{"transactions":[{"id":692111,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-08-11T00:00:10.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":105542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments after May 30, 2026."}],"balance_after":105542,"derivative":{"exercise_price":18,"expiration_date":"2036-08-05","underlying":"Common Stock","underlying_shares":105542},"source":{"system":"sec-edgar","filing":"0001523672-26-000007","document":"form4-08102026_080806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000152367226000007/form4-08102026_080806.xml","form_type":"4"}},{"id":3137525,"issuer":{"id":37706,"kind":"organization","name":"Assertio Holdings, Inc.","symbol":"ASRT"},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director, Pres & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-05-23T00:56:07.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each outstanding option to purchase shares of Zyla's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time was converted into an option to purchase shares of Issuer common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Zyla equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Zyla option as of immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F5","text":"The number of shares of Issuer  common stock subject to each such Parent option is equal to (1) the number of shares of Zyla common stock subject to the corresponding Zyla option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Issuer common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each outstanding option to purchase shares of Zyla's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time was converted into an option to purchase shares of Issuer common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Zyla equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Zyla option as of immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The number of shares of Issuer  common stock subject to each such Parent option is equal to (1) the number of shares of Zyla common stock subject to the corresponding Zyla option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Issuer common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each outstanding option to purchase shares of Zyla's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time was converted into an option to purchase shares of Issuer common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Zyla equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Zyla option as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The number of shares of Issuer  common stock subject to each such Parent option is equal to (1) the number of shares of Zyla common stock subject to the corresponding Zyla option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Issuer common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."}],"balance_after":450000,"derivative":{"exercise_price":0.948,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001104659-20-065545","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808665/000110465920065545/a4.xml","form_type":"4"}},{"id":3137524,"issuer":{"id":37706,"kind":"organization","name":"Assertio Holdings, Inc.","symbol":"ASRT"},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director, Pres & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-05-23T00:56:07.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":603750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each outstanding option to purchase shares of Zyla's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time was converted into an option to purchase shares of Issuer common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Zyla equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Zyla option as of immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F5","text":"The number of shares of Issuer  common stock subject to each such Parent option is equal to (1) the number of shares of Zyla common stock subject to the corresponding Zyla option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Issuer common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each outstanding option to purchase shares of Zyla's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time was converted into an option to purchase shares of Issuer common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Zyla equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Zyla option as of immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The number of shares of Issuer  common stock subject to each such Parent option is equal to (1) the number of shares of Zyla common stock subject to the corresponding Zyla option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Issuer common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each outstanding option to purchase shares of Zyla's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time was converted into an option to purchase shares of Issuer common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Zyla equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Zyla option as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The number of shares of Issuer  common stock subject to each such Parent option is equal to (1) the number of shares of Zyla common stock subject to the corresponding Zyla option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Issuer common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."}],"balance_after":603750,"derivative":{"exercise_price":0.6,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":603750},"source":{"system":"sec-edgar","filing":"0001104659-20-065545","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808665/000110465920065545/a4.xml","form_type":"4"}},{"id":3137523,"issuer":{"id":37706,"kind":"organization","name":"Assertio Holdings, Inc.","symbol":"ASRT"},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director, Pres & CEO"}}],"security":"Common Stock","published_at":"2020-05-23T00:56:07.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":644925,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock of Assertio Holdings, Inc. (\"Issuer\") acquired at the effective time (\"Effective Time\") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the \"Merger Agreement\"), by and among Issuer, Zyla Life Sciences (\"Zyla\") and the other parties thereto.  Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock.  Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit."},{"field":"shares","element":"transactionShares","label":"F3","text":"Totals exclude shares withheld by the Issuer for applicable tax withholdings."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock of Assertio Holdings, Inc. (\"Issuer\") acquired at the effective time (\"Effective Time\") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the \"Merger Agreement\"), by and among Issuer, Zyla Life Sciences (\"Zyla\") and the other parties thereto.  Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock.  Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Totals exclude shares withheld by the Issuer for applicable tax withholdings."}],"balance_after":644925,"source":{"system":"sec-edgar","filing":"0001104659-20-065545","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808665/000110465920065545/a4.xml","form_type":"4"}},{"id":3138716,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-05-21T20:31:15.000Z","date":"2020-05-20","kind":"disposition_to_issuer","acquired":false,"shares":180000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Effective Time, each outstanding option to purchase shares of Issuer's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time, ceased to represent a right to acquire shares of Issuer common stock and was converted, at the Effective Time, into an option to purchase shares of Parent common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Issuer equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Issuer option as of immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The number of shares of Parent common stock subject to each such Parent option is equal to (1) the number of shares of Issuer common stock subject to the corresponding Issuer option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Parent common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option to purchase shares of Issuer's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time, ceased to represent a right to acquire shares of Issuer common stock and was converted, at the Effective Time, into an option to purchase shares of Parent common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Issuer equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Issuer option as of immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The number of shares of Parent common stock subject to each such Parent option is equal to (1) the number of shares of Issuer common stock subject to the corresponding Issuer option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Parent common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option to purchase shares of Issuer's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time, ceased to represent a right to acquire shares of Issuer common stock and was converted, at the Effective Time, into an option to purchase shares of Parent common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Issuer equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Issuer option as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The number of shares of Parent common stock subject to each such Parent option is equal to (1) the number of shares of Issuer common stock subject to the corresponding Issuer option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Parent common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":2.37,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001104659-20-064788","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523672/000110465920064788/a4.xml","form_type":"4"}},{"id":3138715,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-05-21T20:31:15.000Z","date":"2020-05-20","kind":"disposition_to_issuer","acquired":false,"shares":241500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Effective Time, each outstanding option to purchase shares of Issuer's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time, ceased to represent a right to acquire shares of Issuer common stock and was converted, at the Effective Time, into an option to purchase shares of Parent common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Issuer equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Issuer option as of immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The number of shares of Parent common stock subject to each such Parent option is equal to (1) the number of shares of Issuer common stock subject to the corresponding Issuer option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Parent common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option to purchase shares of Issuer's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time, ceased to represent a right to acquire shares of Issuer common stock and was converted, at the Effective Time, into an option to purchase shares of Parent common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Issuer equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Issuer option as of immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The number of shares of Parent common stock subject to each such Parent option is equal to (1) the number of shares of Issuer common stock subject to the corresponding Issuer option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Parent common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option to purchase shares of Issuer's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time, ceased to represent a right to acquire shares of Issuer common stock and was converted, at the Effective Time, into an option to purchase shares of Parent common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Issuer equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Issuer option as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The number of shares of Parent common stock subject to each such Parent option is equal to (1) the number of shares of Issuer common stock subject to the corresponding Issuer option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Parent common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":241500},"source":{"system":"sec-edgar","filing":"0001104659-20-064788","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523672/000110465920064788/a4.xml","form_type":"4"}},{"id":3138714,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-21T20:31:15.000Z","date":"2020-05-20","kind":"disposition_to_issuer","acquired":false,"shares":365500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock and derivative securities of Zyla Life Sciences (\"Issuer\") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the \"Merger Agreement\"), by and among Issuer, Assertio Holdings, Inc. (\"Parent\"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. (\"Merger Sub\"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the \"Effective Time\") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock.  Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Includes unvested time-based restricted stock units representing a contingent right to receive 365,500 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units.  At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock and derivative securities of Zyla Life Sciences (\"Issuer\") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the \"Merger Agreement\"), by and among Issuer, Assertio Holdings, Inc. (\"Parent\"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. (\"Merger Sub\"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the \"Effective Time\") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock.  Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Includes unvested time-based restricted stock units representing a contingent right to receive 365,500 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units.  At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-064788","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523672/000110465920064788/a4.xml","form_type":"4"}},{"id":3224189,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-06T01:45:26.000Z","date":"2020-03-04","kind":"grant","acquired":true,"shares":241500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents non-qualified stock option, 1/3 of which vests on the first anniversary of the grant date and 1/36 of which vests each month thereafter until the option is 100% vested."}],"balance_after":241500,"derivative":{"exercise_price":1.5,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":241500},"source":{"system":"sec-edgar","filing":"0001179110-20-003205","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523672/000117911020003205/edgar.xml","form_type":"4"}},{"id":3224188,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-06T01:45:26.000Z","date":"2020-03-04","kind":"grant","acquired":true,"shares":165500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant."}],"balance_after":165500,"source":{"system":"sec-edgar","filing":"0001179110-20-003205","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523672/000117911020003205/edgar.xml","form_type":"4"}},{"id":3326662,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-03T00:44:07.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents non-qualified stock option, 1/3 of which vests on the first anniversary of the grant date and 1/36 of which vests each month thereafter until the option is 100% vested."}],"balance_after":180000,"derivative":{"exercise_price":2.37,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001179110-20-000060","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523672/000117911020000060/edgar.xml","form_type":"4"}},{"id":3388492,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":25097,"kind":"person","name":"SMITH TODD N","position":1,"cik":"0001523672","reported_name":"SMITH TODD N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-24T23:44:58.000Z","date":"2019-10-23","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001179110-19-011226","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523672/000117911019011226/edgar.xml","form_type":"4"}}]}